Breaks Categories: News

ThursdayJul 08, 2021 12:47 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Announces Ultimate Brain Nutrients ACTIVATE, a Breakthrough Nutraceutical Formulation

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based products for heart and brain health, has unveiled a game-changing nutraceutical formulation: Ultimate Brain Nutrients ACTIVATE(TM) (“UBN”). According to the company, clinical studies indicate that the proprietary formulation naturally increases key brain activity by as much as 46%. Other results from studies show that ACTIVATE significantly improves human cognitive behavior and mental focus by activating areas of the brain that are key in attention, memory, mood and quick reaction times. HYEX has devoted more than two decades in research on the formulation, which included approximately 100 clinical studies…

Continue Reading

WednesdayJul 07, 2021 1:48 pm

BioMedNewsBreaks – Numinus Wellness Inc. (TSX.V: NUMI) Announces Plans to Combine Expertise, Create Centre for Excellence in Psychedelic Neurology

Numinus Wellness (TSX.V: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has agreed to acquire the Neurology Centre of Toronto ("NCT") pursuant to a purchase agreement dated July 2, 2021. According to the update, Numinus and NCT founder Dr. Evan Lewis plan to expand NCT into a comprehensive clinical neurology treatment centre with a unique specialization in the application of psychedelics in the field of neurology. “This acquisition represents an exciting opportunity for NCT and Numinus to combine medical, clinical and academic expertise to help create a new discipline and…

Continue Reading

WednesdayJul 07, 2021 1:40 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils Study Data Showing 97% of Vivos Patients Report Reaching Desired Outcome

Vivos Therapeutics (NASDAQ: VVOS) has released data from an independent patient survey related to its proprietary Vivos treatment for dental tissue anomalies and dentofacial malformations associated with obstructive sleep apnea (“OSA”) and other debilitating health conditions. The study reported that approximately 97% of patients surveyed said that they had achieved their desired outcome from the Vivos treatment for their OSA. Other study results show that 63% of patients reported that they depend on their dentist’s advice as they look for lasting solutions that addresses the root cause of their OSA and 29% indicated they searched for nonsurgical alternatives to current…

Continue Reading

WednesdayJul 07, 2021 1:12 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Key Board Appointment of Mary L. Rotunno

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Mary L. Rotunno, J.D. to its board of directors. “Mary brings to our team more than 30 years of leadership experience, which began with serving patients as a registered nurse and transitioned to serving clients in health care law, both allowing her to pursue her steadfast commitment to helping others and advancing the future of mental health and wellness,” said VistaGen CEO Shawn Singh.…

Continue Reading

WednesdayJul 07, 2021 10:07 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Strategic Collaboration with the University of Michigan

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced an agreement with the University of Michigan to perform research related to Tryp's Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program. According to the update, the collaboration is part of a series of upcoming bridging studies designed to expand Tryp's intellectual property portfolio for the company's novel TRP-8803 drug formulation compared with conventional oral formulations of synthetic psilocybin. The studies will also facilitate the advancement of TRP-8803 into Phase 2b clinical trials. “We are excited to initiate our…

Continue Reading

ThursdayJul 01, 2021 12:53 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Business Update, Progress on Driving Berubicin’s Development

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided a business update. Among the highlights, the company reported on its continued progress to drive Berubicin towards commercialization for the treatment of glioblastoma multiforme (“GBM”). “In the last 60 days alone, we have achieved fundamental clinical, regulatory and corporate milestones that together demonstrate CNS’ operational, strategic and financial strengths. We are continuously de-risking our Berubicin clinical program by driving development of this truly novel treatment forward as expeditiously as possible. In a…

Continue Reading

WednesdayJun 30, 2021 2:54 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Enters Strategic Partnerships to Amplify Message Through Global Expansion

RYAH Group (CSE: RYAH) today announced that it has entered into two public relations, investor relations and/or marketing arrangements. These include a service agreement with KCSA Strategic Communications, through RYAH Medtech Inc., under which KCSA will provide certain public relations and corporate communications services, as well as a service agreement with EastWest Asset Management LLC, an affiliate of CFN Media Group, through RYAH Medtech, under which EastWest will provide certain investor relations, marketing and corporate communication services to the company. “We continue to remain focused and disciplined in ensuring our clients, investors and our partners remain informed of our vision,…

Continue Reading

WednesdayJun 30, 2021 11:11 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Finalizes Supply Agreement with Two German Companies for COVID-19 PCR Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has inked a master supply agreement with two German diagnostics, testing, and medical logistics companies: Beovita GmbH & Co. KG and Tackleberries GmbH. The two companies run 10 COVID-19 test centers in Berlin. The supply agreement outlines the delivery of approximately 1,000 of XPhyto’s proprietary Covid-ID Lab tests to test centers in Berlin. Delivery is scheduled to begin this week, followed by a brief trial period to integrate and evaluate XPhyto’s new PCR test system with commercial operations expected to commence upon delivery…

Continue Reading

WednesdayJun 30, 2021 10:12 am

BioMedNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2021 Financial Results, Corporate Highlights

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its financial results for fiscal year ended March 31, 2021; the company also provided a corporate update, noting that its PALISADE-1 phase 3 trial designed to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (“SAD”) is under way. The announcement also noted that the company is preparing to initiate several exploratory phase 2A clinical trials of…

Continue Reading

TuesdayJun 29, 2021 11:13 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives FDA Fast Track Status for Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the U.S. Food and Drug Administration granted Fast Track Designation for Berubicin, the company’s lead investigational drug. The status was received for the company’s evaluation of Berubicin for the treatment of patients with recurrent glioblastoma multiforme (“GBM”). An anthracycline, Berubicin falls in a class of anticancer agents that are among the most powerful chemotherapy drugs, proven to be effective against more types of cancer than any other category of chemotherapeutic agents. Fast…

Continue Reading